More than three years after GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) exploded into mainstream awareness as weight loss treatments, the scientific picture has matured considerably from the early mix of extraordinary clinical trial results and limited real-world data. The evidence base for GLP-1 medications’ effectiveness and safety has expanded enormously, long-term outcome data has begun to emerge, and the medical community’s understanding of both the benefits and limitations of these treatments has become substantially more nuanced than the initial wave of coverage suggested. Here is what the science as of mid-2026 actually shows about GLP-1 medications for weight loss.

What the Long-Term Data Shows

The SELECT trial, which followed cardiovascular outcomes in more than 17,000 adults with overweight and established cardiovascular disease over a median of 34 months, provided the most important long-term data to emerge from GLP-1 research. The trial found that semaglutide reduced major cardiovascular events – heart attack, stroke, and cardiovascular death – by 20% compared to placebo, a finding that goes beyond weight loss to suggest direct cardiovascular benefits that may be partly independent of the weight reduction effect. This finding has significantly changed how cardiologists view GLP-1 medications, shifting them from weight loss drugs with cardiac implications to cardiac protective drugs with weight loss benefits.

• Average weight loss in clinical trials for semaglutide (Wegovy) has consistently shown 15-20% of body weight over 68 weeks, which significantly exceeds what any previous approved weight loss medication achieved.
• Weight regain after stopping GLP-1 medications is significant and well-documented – most patients regain the majority of lost weight within one to two years of discontinuation, which has important implications for how these medications should be framed: as ongoing treatments rather than courses, similar to how blood pressure medication is used.
• Side effects, primarily gastrointestinal – nausea, vomiting, diarrhea, constipation – affect a significant proportion of users, particularly in the dose escalation phase. Most side effects are transient and manageable, but a meaningful minority of patients discontinue treatment because of intolerable gastrointestinal symptoms.
• Muscle mass loss during GLP-1-induced weight reduction has emerged as a significant concern, with studies showing that a proportion of the weight lost on GLP-1 medications comes from lean mass rather than fat. Resistance training and adequate protein intake are now routinely recommended alongside GLP-1 treatment to minimize this effect.

Access and Affordability in 2026

The access picture for GLP-1 medications has improved significantly since 2023 when the combination of explosive demand and limited manufacturing capacity created persistent shortages. Manufacturing capacity has been substantially expanded by both Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound), and several generic and biosimilar versions have entered or are approaching the market in various countries, beginning to create price competition in a drug class whose list prices – $900-1,300 per month without insurance coverage – have been a major access barrier.

Insurance coverage for GLP-1 medications remains inconsistent. Medicare coverage for weight loss indications specifically was prohibited until recent legislative changes that are still being implemented, and private insurer coverage varies enormously between plans and employers. The cost-effectiveness evidence that has accumulated – showing that the cardiovascular and metabolic benefits of these medications may offset their costs in high-risk populations – is beginning to influence coverage decisions, but the access disparities between insured and uninsured patients and between employer plan types remain a significant public health concern.